PolyMedica settles Medicare over-billing charges
This article was originally published in The Gray Sheet
Tentative settlement with the Department of Justice will include a $35 mil. payment and a corporate integrity agreement without admission of wrongdoing, the firm says. The deal follows a three-year DoJ investigation into the company's Medicare billing and claims documentation practices. "It's important to note the agreements are still being negotiated and are subject to approval by the OIG and DoJ," PolyMedica Chairman Samuel Shanaman says in a release. The diabetes and respiratory product firm notes that the U.S. Attorney's Office for the Southern District of Florida "will not bring criminal charges against the company" (1"The Gray Sheet" Feb. 16, 2004, p. 12)...
You may also be interested in...
PolyMedica will seek growth through acquisitions to offset an average 3% reduction in reimbursement rates for its diabetes products that will become effective in 2005 under the recent Medicare law
A medtech industry group is asking the Trump administration to clarify if small medical device companies that have equity investors qualify for small business loans and forgiveness under the coronavirus relief package.
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.